Cancer Gene Therapy:UNC5B能够介导膀胱癌细胞的G2/M期阻滞

2020-05-25 AlexYang MedSci原创

在许多类型的癌症中,UNC5B是一个已知的肿瘤抑制基因。作为一个跨膜蛋白,UNC5B同样能够以P53依赖的方式诱导细胞凋亡。

在许多类型的癌症中,UNC5B是一个已知的肿瘤抑制基因。作为一个跨膜蛋白,UNC5B同样能够以P53依赖的方式诱导细胞凋亡。

最近,有研究人员在膀胱癌细胞中,通过质谱分析和生物信息学分析,阐释了UNC5B能够通过G2/M细胞周期阻滞来抑制细胞增殖。另外,通过与CDC14A和P53的结合,UNC5B能够在Ser-315位点对P53蛋白进行去磷酸化。该去磷酸化过程能够通过减少细胞周期蛋白B1的表达和增加p-CDK21的表达促进G2/M细胞周期阻滞,从而抑制肿瘤的增殖。体外试验中,CDC14A敲除能够抑制UNC5B诱导的G2/M细胞周期阻滞,并消除体内试验中UNC5B对肿瘤增殖的抑制作用。

最后,研究人员指出,他们的结果表明了UNC5B介导的细胞周期阻滞可能是膀胱癌治疗的潜在方法。

原始出处:

Yexiang Huang, Yuyan Zhu, Zhe Zhang et al. UNC5B mediates G2/M phase arrest of bladder cancer cells by binding to CDC14A and P53. Cancer Gene Therapy. 06 May 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049300, encodeId=f7852049300b9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jan 01 02:54:26 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739014, encodeId=0cb81e39014ab, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Oct 05 12:54:26 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252699, encodeId=6a0c125269939, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed May 27 03:54:26 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039976, encodeId=832110399e638, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Mon May 25 15:54:26 CST 2020, time=2020-05-25, status=1, ipAttribution=)]
    2021-01-01 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049300, encodeId=f7852049300b9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jan 01 02:54:26 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739014, encodeId=0cb81e39014ab, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Oct 05 12:54:26 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252699, encodeId=6a0c125269939, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed May 27 03:54:26 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039976, encodeId=832110399e638, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Mon May 25 15:54:26 CST 2020, time=2020-05-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049300, encodeId=f7852049300b9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jan 01 02:54:26 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739014, encodeId=0cb81e39014ab, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Oct 05 12:54:26 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252699, encodeId=6a0c125269939, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed May 27 03:54:26 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039976, encodeId=832110399e638, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Mon May 25 15:54:26 CST 2020, time=2020-05-25, status=1, ipAttribution=)]
    2020-05-27 yxch36
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049300, encodeId=f7852049300b9, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jan 01 02:54:26 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739014, encodeId=0cb81e39014ab, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Mon Oct 05 12:54:26 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252699, encodeId=6a0c125269939, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Wed May 27 03:54:26 CST 2020, time=2020-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039976, encodeId=832110399e638, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Mon May 25 15:54:26 CST 2020, time=2020-05-25, status=1, ipAttribution=)]
    2020-05-25 留走人康

    膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效

    0

相关资讯

Sci Rep:完全病理下降膀胱癌患者泌尿外泌体展现出了残存的癌症表型

侵袭性泌尿膀胱癌在膀胱切除术后具有很高的复发率,尽管膀胱切除术时具有明显的完全下降。外泌体是纳米尺寸的囊泡,在细胞之间的交流中具有重要作用,并被假设能够导致癌症扩散和复发。

Modern Pathology:免疫组化和分子分析整合能够改善高等级肿瘤的诊断

前列腺腺癌和尿路上皮癌具有典型的不同的形态和免疫组化特性。然而,高等级前列腺癌和尿路上皮癌有时会明显的表现出形态特征和免疫组化特征的重复,从而导致误诊和错误治疗。该诊断瓶颈在之前经历过放疗/激素治疗的

Oncogene:PAK4可作为膀胱癌的治疗靶标

肌层浸润膀胱癌(MIBCs)是具有侵袭性的生殖泌尿系恶性肿瘤。膀胱的转移性尿路上皮癌在目前的化疗下无法治愈,并且能导致早期死亡。之前的研究鉴定了MIBCs的分子亚型,并且对前线疗法具有不同的敏感性,也

Sci Rep:代谢不健康状态患者的膀胱癌发病率增加

最近,有研究人员评估了代谢健康状态和膀胱癌发生率之间的相关性,数据来自韩国国家健康保险系统和国家健康检查(NHC)数据库的代表性数据。

Eur Urol:分子亚型和免疫浸润对肌层浸润性膀胱癌新辅助Pembrolizumab治疗的病理响应和结果影响

PURE-01研究(NCT02736266)评估了肌层浸润膀胱癌(MIBC)中根治性膀胱切除术(RC)前使用pembrolizumab的治疗情况。最近,有研究人员评估了pembrolizumab和RC

durvalumab联合tremelimumab治疗膀胱癌:无法改善OS

阿斯利康近日宣布,一项针对PD-L1抑制剂Imfinzi(durvalumab)的III期研究(单药治疗以及与抗CTLA4抗体tremelimumab联合使用)未能达到主要终点。